Adagene Inc. cotiza a 2.46 USD y tiene una capitalización bursátil de $165M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatm…
| Periodo | 2023-04 | 2022-11 | 2022-08 | 2022-04 |
|---|---|---|---|---|
| Real | $-0.15 | $-0.36 | $-0.34 | $-0.25 |
| Estimado | $-0.36 | $-0.36 | $-0.53 | $-0.32 |
| Sorpresa | +58.3% | +0.0% | +35.8% | +21.9% |
| Métrica | ADAG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -279.5% | -38.6% | -240.9% |
| Net Margin | -229.6% | -33.6% | -196.0% |
| FCF Margin | -204.3% | -13.9% | -190.5% |
| ROE | -49.8% | -40.4% | -9.4% |
| ROA | -22.5% | -32.0% | +9.5% |
| Current Ratio | 3.07 | 2.84 | +0.23 |
| Debt / Equity | 0.03 | 0.28 | -0.25 |